関連する実験動画
Updated: May 9, 2026

14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
エンジニアリングされたサイクロチドによるp53腫瘍抑制経路のインビボ活性化
Yanbin Ji1, Subhabrata Majumder2, Melissa Millard1
1Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90033, USA.
Journal of the American Chemical Society
|July 16, 2013
まとめ
エンジニアリングされたサイクロチドはHdm2とHdmXを標的とし,がん細胞の生存を抑制します. この新しいMCo-PMIペプチドは,野生型のp53腫瘍に対する安定性と有効性を示し,有望ながん治療を提供している.
科学分野:
- バイオケミストリー バイオケミストリー
- 分子生物学は分子生物学である.
- がん研究 がん研究
背景:
- Hdm2とHdmXの過剰発現は,がん細胞のp53腫瘍抑制経路を無効化する.
- Hdm2/HdmXをターゲットにすることは,野生型のp53がんの治療戦略です.
- p53を模倣する線形ペプチドは強力なHdm2/HdmXアンタゴニストであるが,安定性と生体利用性が悪い.
研究 の 目的:
- 癌治療のためのHdm2/HdmXの安定した,生物利用可能なアンタゴニストとしてサイクロチドMCoTI-Iを設計する.
- エンジニアリングされたサイクロチドMCo-PMIがp53の分解を阻害し,がん細胞に対する細胞毒性の効果を評価する.
主な方法:
- MCo-PMIを作成するために,サイクロチドMCoTI-Iのエスカファードのエンジニアリング.
- Hdm2およびHdmX.へのMCo-PMI結合親和性を評価する.
- 人間の血清におけるMCo-PMIの安定性を評価する.
- MCo-PMIの細胞毒性およびp53経路の活性化を野生型のp53がん細胞系で in vitroおよびin vivoでテストする.
主要な成果:
- エンジニアリングされたサイクロチドMCo-PMIは,Hdm2とHdmXの両方に低いナノモラー結合親和性を示しました.
- MCo-PMIは,ヒトの血清において高い安定性を示した.
- MCo-PMIは,野生型のp53がん細胞系に対して細胞毒性であった.
- MCo-PMIはp53腫瘍抑制経路をインビトロとインビボの両方で活性化しました.
結論:
- サイクロチドMCoTI-Iは,Hdm2/HdmXアンタゴニストを開発するための効果的な支架です.
- MCo-PMIは,p53経路を安定させることで,野生型p53によるがんの治療に有望な治療候補である.
- エンジニアリングされたサイクロチドは,細胞内タンパク質-タンパク質の相互作用をターゲットにするために,線形ペプチドの制限を克服することができます.
関連する概念動画
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

